Abstract OT2-3-08: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor-based treatment – BELLE-3
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS617-TPS617
◽
Keyword(s):
2008 ◽
Vol 26
(30)
◽
pp. 4883-4890
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 33
(6)
◽
pp. 594-601
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. TPS102-TPS102
◽
Keyword(s):
2012 ◽
Keyword(s):